University of Alabama at Birmingham School of Medicine, USA.
Curr HIV/AIDS Rep. 2011 Sep;8(3):192-9. doi: 10.1007/s11904-011-0084-6.
Cervical cancer remains the second commonest cancer among women worldwide, and more than 85% of the global burden of this disease occurs in the developing world. HIV-infected women have a higher likelihood of developing persistent high-risk human papillomavirus (HPV) infection, precancer, and invasive cervical cancer than seronegative women. Although highly effective primary and secondary prevention strategies are currently available, they remain inaccessible to the vast majority of women. Because of their simplicity and affordability, see-and-treat cervical cancer screening modalities have the potential to substantially improve women's access to cancer prevention, as well as to create much needed infrastructure for future molecular-based cervical screening and HPV vaccination programs. Additional data addressing the effectiveness of see-and-treat approaches for HIV-infected women are urgently needed. Studies informing best practice guidelines on when to start, when to stop, and how frequently to screen HIV-infected women within the see-and-treat paradigm would be of great value.
宫颈癌仍然是全世界女性中第二常见的癌症，全球超过 85%的宫颈癌负担发生在发展中国家。与血清阴性的女性相比，感染 HIV 的女性更有可能持续感染高危型人乳头瘤病毒（HPV）、癌前病变和浸润性宫颈癌。尽管目前有非常有效的一级和二级预防策略，但绝大多数妇女仍然无法获得这些策略。由于其简单性和可负担性，观察和治疗宫颈癌筛查方法有可能大大改善妇女获得癌症预防的机会，并为未来基于分子的宫颈癌筛查和 HPV 疫苗接种计划建立急需的基础设施。迫切需要更多的数据来评估观察和治疗方法对感染 HIV 的女性的有效性。在观察和治疗模式下，告知最佳实践指南何时开始、何时停止以及如何频繁地对感染 HIV 的女性进行筛查的研究将具有重要价值。
